A group of bipartisan US senators has introduced a bill aimed at increasing oversight of foreign ownership in the country’s pharmaceutical sector. The Pharmaceutical Investment Oversight and Accountability Act, presented by Senators Rick Scott, Kirsten Gillibrand, and Elizabeth Warren, seeks to provide annual reports to Congress on foreign investments in pharmaceutical manufacturing and associated technologies. The legislation aims to enhance transparency regarding the ownership and control of companies supplying medications to the American populace.
The senators emphasized the necessity for Americans, particularly seniors, to be informed about the entities ultimately managing the medications crucial to their health. Concerns were raised about the lack of comprehensive knowledge in Washington regarding foreign ownership throughout the pharmaceutical supply chain, encompassing drug manufacturing facilities, ingredient production, and sensitive clinical data. The senators highlighted potential risks to national security and public health if critical supplies were disrupted due to geopolitical tensions.
Notably, the United States heavily relies on China and India for essential materials and active pharmaceutical ingredients required for manufacturing numerous generic drugs. The senators stressed the importance of increased oversight to ascertain the extent of foreign influence while ensuring continued trustworthy international investments in the sector. Efforts to bolster federal oversight and transparency in understanding the impact of foreign capital on American healthcare infrastructure were deemed crucial.
Experts testifying before the committee underscored China’s expanding presence in biotechnology research, clinical trials, and pharmaceutical innovation, signaling potential challenges to US competitiveness and supply chain resilience. Recommendations were made to tighten oversight on Chinese investments in US biotech firms, address gaps in existing laws, and enforce disclosure rules mandating identification of beneficial ownership and foreign control in strategic sectors. Diversification of production, enhancement of domestic manufacturing, and collaboration with allies were suggested to reduce reliance on Chinese suppliers for pharmaceutical inputs.
Discussing India’s role, experts proposed the country as a key partner in decreasing dependency on China. They advocated for integrating pharmaceutical cooperation into the broader US-India strategic partnership, alongside collaboration in areas like semiconductors, artificial intelligence, and critical minerals. Additionally, suggestions were made for the US Development Finance Corporation to support pharmaceutical manufacturing in India through mechanisms such as loan guarantees and financing tools.
